SciSparc Ltd. (NASDAQ: SPRC) is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 (formerly THX-110) for the treatment of Tourette syndrome and for the treatment of obstructive sleep apnea; SCI-160 (formerly THX-160) for the treatment of pain; and SCI-210 (formerly THX-210) for the treatment of autism spectrum disorder and epilepsy.
| Website | https://scisparc.com/ |
| Employees | 3 (1 on RocketReach) |
| Industry | Biotechnology Research |
| Keywords | Pharma, Pharmaceutical, Cannabinoids, Clinical Stage, Cannabinoid Therapeutics, Drug Development, Specialty Pharmaceuticals, Biotechnology, Cannabis Research, Therapeutics, Pharmaceutical Research, Clinical Trials, Drug Discovery, Biopharma, Medicine, Health, Science, Research, Technology, Healthcare |
Looking for a particular SciSparc employee's phone or email?
SciSparc Questions
Oz Adler is the CEO of SciSparc.
1 people are employed at SciSparc.
Top SciSparc Employees
Related Companies
